Clinical Study of the Safety and Efficacy of BCMA CAR-NK
- Conditions
- ImmunotherapyMultiple Myeloma
- Interventions
- Drug: Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
- Registration Number
- NCT05652530
- Lead Sponsor
- Shenzhen Pregene Biopharma Co., Ltd.
- Brief Summary
The goal of this clinical trial is to study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) in Patients with Relapsed/Refractory Multiple Myeloma
Primary Endpoints:
To evaluate the safety and tolerability of patients with relapsed/refractory multiple myeloma (RR/MM) after BCMA CAR-NK infusion.
To determine the maximum tolerated dose (MTD) and/or subsequent recommended dose (RD) of BCMA CAR-NK in patients with RR/MM.
Secondary Endpoints:
To preliminarily evaluate the effectiveness of BCMA CAR-NK in patients with RR/MM.
To preliminarily evaluate the pharmacokinetic parameters of BCMA CAR-NK cells in patients with RR/MM.
To preliminarily evaluate BCMA CAR-NK cell survival in subjects blood in relation to efficacy, adverse events and relevant biomarker levels.
To preliminarily evaluate the relationship between donors and subjects KIR-Ligand mismatch and safety \& efficacy.
To preliminarily evaluate the impact of the degree of HLA genotype matching between donors and subjects on the survival of BCMA CAR-NK cells in the subjects blood.
Subjects are enrolled and treated with lymphocyte clearance chemotherapy (including pre-clearance evaluation), pre-infusion evaluation and BCMA CAR-NK cells infusion and enter the follow-up period after the end of the DLT observation period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 19
- Age 18 years or above, no gender preference.
- Patients who have received at least 3 prior lines of treatment for multiple myeloma and have failed at least proteasome inhibitor and immunomodulator therapy; Each line has at least 1 complete treatment cycle unless the best remission status for that treatment is documented as progressive disease (PD) (as per the IMWG efficacy evaluation criteria published in 2016, Appendix 4); PD must be documented during or within 12 months after receiving the last treatment.
- Presence of measurable lesions at screening, which are defined as any of the following situations:
Serum M protein≥1 g/dL (≥10 g/L) Urinary M protein≥200 mg/24 hours Serum free light chain (FLC): abnormal serum FLC ratio (<0.26 or >1.65) and involved FLC≥10 mg/dL (100 mg/L)
- ECOG score (Appendix 1): 0~1.
- Expected survival≥3 months.
- The following test values within 7 days prior to lymphocyte clearance meet the following criteria:
Hematology Absolute lymphocyte count:≥0.5×109/L[Granulocyte colony-stimulating factor (G-CSF) is allowed, but subjects should not have received this supportive therapy within 7 days prior to laboratory test during the screening period] Absolute neutrophil count:≥1.0×10^9 /L[Granulocyte colony-stimulating factor (G-CSF) is allowed, but subjects should not have received this supportive therapy within 7 days prior to laboratory test during the screening period].
Platelets:Subjects platelet count ≥50 x 10^9/L (subjects must not receive transfusion support within 7 days prior to laboratory test during the screening period) Hemoglobin:≥8.0 g/dL (recombinant human erythropoietin is allowed) [subjects have not received a red blood cell (RBC) transfusion within 7 days prior to laboratory test during the screening period].
Liver Total bilirubin (serum) :Total bilirubin (serum) ≤1.5 × ULN AST and ALT:≤3× ULN
- Peripheral venous pathway meets the requirements of intravenous drip.
- Subjects agree to use reliable methods for contraception from the time of signing the informed consent till 1 year after the transfusion.
- Voluntary participation in the clinical trial and signing of the informed consent form.
- Subjects who have had a severe anaphylactic reaction.
- Subjects who received the following anti-MM therapy within a specific time prior to lymphocyte clearance.
Small molecule targeted therapy within 2 weeks or 5 half-lives (whichever is longer).
Large-molecule drug within 4 weeks or 2 half-lives (whichever is longer). Cytotoxic drugs, modern Chinese medicine preparations with antitumor effects within 2 weeks.
Immunomodulators therapy within 1 week.
- Subjects who have received a live or attenuated vaccine within 4 weeks prior to lymphocyte clearance.
- Subjects who have received the following therapy within 7 days prior to lymphocyte clearance, or that requires long-term treatment during the study period according to the investigators:
Systemic steroid therapy (except for inhaled one or topical use). Immunosuppressive therapy. Treatment of graft-versus-host response.
- Subjects presenting with incomplete recovery or stabilization to grade 1 (NCI-CTCAE v5.0) of toxicity (including peripheral neuropathy) caused by prior treatments.
- Cardiac disease: episode of myocardial infarction≤6 months prior to lymphocyte clearance; episode of unstable angina, severe arrhythmia as judged by the investigators, or coronary artery bypass graft≤3 months prior to lymphocyte clearance.
- Women who are pregnant or breastfeeding.
- Subjects who, in the opinion of the investigators, have any clinical or laboratory test abnormalities or other reasons that make them ineligible to participate in this clinical study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description BCMA CAR-NK Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) -
- Primary Outcome Measures
Name Time Method Safety and Toxicity Assessment per Adverse Event reporting classified according to CTCAE V5.0 Day 28 per Adverse Event reporting classified according to CTCAE V5.0
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Henan Cancer Hospital
🇨🇳Zhengzhou, Henan, China